Prevalence and Antifungal Susceptibility patterns of Candida Isolated on CHROMagarTMCandida at a Tertiary Referral Hospital, Eastern Uganda
Microbiology Research Journal International,
Background: Pregnant women are susceptible to vaginal candidiasis and maternal vulvovaginal candidiasis is a major risk factor for colonization and/or infection of the infant. The purpose of this study was to determine the prevalence and antifungal patterns of albicans and non-albicans Candida among pregnant women attending a tertiary referral hospital.
Methods: Vaginal discharge- cotton swabs were self-collected from pregnant women clinically proven to have vulvovaginal candidiasis at the antenatal clinic of a tertiary referral hospital between January and July 2018. Microscopy and culture on Sabouraud's Dextrose Agar with chloramphenicol was done on the vaginal discharge-cotton swabs. Confirmatory fungal identification was done using CHROM agarTM Candida. Antifungal susceptibility testing was carried out using the standardized Kirby Bauer method.
Results: Candida were isolated from 50.81% (126/249) of the swabs and included C. albicans (80.16%, 101/126), C. glabrata (19.05% (24/126) and C. krusei (0.79%, 1/126). Candida albicans showed resistance to amphotericin B (70.63%, 89/126), clotrimazole (11.9%, 15/126), nystatin (3.17%, 4/126), fluconazole (23.02%, 29/126), and itraconazole (17.46%, 22/126). Among the non-albican Candida species, C. glabrata showed resistance to fluconazole (100% ,24/24), amphotericin B (100% ,24/24), clotrimazole (14.29%, 18/24), nystatin (1.59%, 2/24), and itraconazole (18.25%, 23/24). C. krusei showed resistance to fluconazole (100%, 1/1), amphotericin B (100%,1/1), and itraconazole (100%, 1/1).
Conclusion: The candida species commonly associated with VVC in Eastern Uganda are C. albicans C. glabrata and C. krusei. Antifungal resistance was highly prevalent among the candida isolated. The use of CHROMagarTMCandida media for identification of clinically relevant Candida should be adopted instead of conventional methods that are tedious and time consuming such that treatment is based on laboratory evidence.
- Vulvovaginal candidiasis
- antifungal susceptibility
How to Cite
de Leon EM, Jacober SJ, Sobel JD, Foxman B. Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC infectious diseases. 2002;2:1.
Bitew A, Abebaw Y. Vulvovaginal candidiasis: Species distribution of Candida and their antifungal susceptibility pattern. BMC Womens Health. 2018; 18(1):94.
Consolaro ME, Albertoni TA, Svidzinski AE, Peralta RM, Svidzinski TI. Vulvovaginal candidiasis is associated with the production of germ tubes by Candida albicans. Mycopathologia. 2005;159(4): 501-7.
Tang Y, Yu F, Huang L, Hu Z. The changes of antifungal susceptibilities caused by the phenotypic switching of Candida species in 229 patients with vulvovaginal candidiasis. Journal of Clinical Laboratory Analysis. 2019;33(1): e22644.
Ge SH, Wan Z, Li J, Xu J, Li RY, Bai FY. Correlation between azole susceptibilities, genotypes, and ERG11 mutations in Candida albicans isolates associated with vulvovaginal candidiasis in China. Antimicrob Agents Chemother. 2010;54(8): 3126-31.
Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. Azole antifungal resistance in Candida albicans and emerging non-albicans Candida Species. Frontiers in Microbiology. 2017;7:2173.
Chokoeva A, Kouzmanov A, Ivanova Z, Zisova L, Amalie G, Petleshkova P, et al. [Investigation on antifungal susceptibility of Candida yeasts in pregnant patients with confirmed vulvovaginal Candidiasis and their newborns.]. Akush Ginekol (Sofiia). 2016;55(4):20-9.
Amouri I, Sellami H, Borji N, Abbes S, Sellami A, Cheikhrouhou F, et al. Epidemiological survey of vulvovaginal candidosis in Sfax, Tunisia. Mycoses. 2011;54(5):e499-e505.
Pfaller MA, Jones RN, Castanheira M. Regional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period 2006-2011. Mycoses. 2014;57(10):602- 11.
Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Nagy E, Dobiasova S, et al. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: Geographic and temporal trends from the artemis disk antifungal surveillance program, 2001 to 2005. Journal of clinical microbiology. 2008; 46(2):515-21.
Guzel AB, Aydin M, Meral M, Kalkanci A, Ilkit M. Clinical characteristics of Turkish women with Candida krusei vaginitis and antifungal susceptibility of the C. krusei isolates. Infect Dis Obstet Gynecol. 2013; 698736.
Mukasa KJ, Herbert I, Daniel A, Sserunkuma KL, Joel B, Frederick B. Antifungal susceptibility patterns of vulvovaginal Candida species among women attending antenatal clinic at Mbarara Regional Referral Hospital, South Western Uganda. British Microbiology Research Journal. 2015;5(4):322-31.
Devi L, Maheshwari M. Speciation of Candida species isolated from clinical specimens by using chrom agar and conventional methods. 2018;11(2)136-145.
Hu Z, Zhou W, Mu L, Kuang L, Su M, Jiang Y. Identification of cytolytic vaginosis versus vulvovaginal candidiasis. Journal of Lower Genital Tract Disease. 2015;19(2): 152-5.
Nadeem SG, Hakim ST, Kazmi SU. Use of CHROMagar Candida for the presumptive identification of Candida species directly from clinical specimens in resource-limited settings. Libyan J Med. 2010;5.
Odds FC, Bernaerts R. CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species. Journal of Clinical Microbiology. 1994; 32(8):1923-9.
Vijaya D, Dhanalakshmi TA, Kulkarni S. Changing trends of vulvovaginal candidiasis. J Lab Physicians. 2014;6(1): 28-30.
Morris AJ, Rogers K, McKinney WP, Roberts SA, Freeman JT. Antifungal susceptibility testing results of New Zealand yeast isolates, 2001-2015: Impact of recent CLSI breakpoints and epidemiological cut-off values for Candida and other yeast species. J Glob Antimicrob Resist. 2018;14:72-7.
Khan M, Ahmed J, Gul A, Ikram A, Lalani FK. Antifungal susceptibility testing of vulvovaginal Candida species among women attending antenatal clinic in tertiary care hospitals of Peshawar. Infect Drug Resist. 2018;11:447-56.
Tumbarello M, Sanguinetti M, Trecarichi EM, La Sorda M, Rossi M, de Carolis E, et al. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: Risk factors, antifungal treatment and outcome. The Journal of Antimicrobial Chemotherapy. 2008;62(6):1379-85.
Kullberg BJ, Arendrup MC. Invasive Candidiasis. The New England Journal of Medicine. 2015;373(15):1445-56.
Arendrup MC, Patterson TF. Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms and Treatment. The Journal of Infectious Diseases. 2017; 216(suppl_3):S445-S51.
Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical infectious diseases : An official publication of the Infectious Diseases Society of America. 2016;62(4):409-17.
Lewis JS, 2nd, Wiederhold NP, Wickes BL, Patterson TF, Jorgensen JH. Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. Antimicrobial agents and Chemotherapy. 2013;57(9):4559-61.
Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, et al. Increasing echinocandin resistance in Candida glabrata: Clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clinical infectious diseases : An official publication of the Infectious Diseases Society of America. 2013; 56(12):1724-32.
Abstract View: 1601 times
PDF Download: 671 times